Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 105-112 , March 2006

Differential effects of PDGF-BB on matrix metalloproteases and cytokine release in fibroblasts of Type 2 diabetic patients and normal controls in vitro

  • Ralf Lobmann

      Affiliations

    • Department of Endocrinology and Metabolism, Magdeburg University Medical School, Magdeburg 39120, Germany
    • Corresponding Author InformationCorresponding author. Department of Endocrinology and Metabolism, Magdeburg University Medical School, Leipziger Strasse 44, Magdeburg 39120, Germany. Tel.: +49 391 67 15445; fax: +49 391 67 15448.
    • ,
  • Thomas Pap

      Affiliations

    • Institute of Experimental Rheumatology, Magdeburg University Medical School, Magdeburg 39120, Germany
    • ,
  • Andreas Ambrosch

      Affiliations

    • Department of Clinical Microbiology, Magdeburg University Medical School, Magdeburg 39120, Germany
    • ,
  • Katrin Waldmann

      Affiliations

    • Department of Endocrinology and Metabolism, Magdeburg University Medical School, Magdeburg 39120, Germany
    • ,
  • Wolfgang König

      Affiliations

    • Department of Clinical Microbiology, Magdeburg University Medical School, Magdeburg 39120, Germany
    • ,
  • Hendrik Lehnert

      Affiliations

    • Department of Endocrinology and Metabolism, Magdeburg University Medical School, Magdeburg 39120, Germany

Received 21 December 2004 ,Revised 26 May 2005 ,Accepted 31 May 2005.

References 

  1. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. Journal of the American Podiatric Medical Association. 2002;92:12–18
  2. Beer HD, Longaker MT, Werner S. Reduced expression of PDGF and PDGF receptors during impaired wound healing. Journal of Investigative Dermatology. 1997;109:132–138
  3. Bullen EC, Longaker MT, Updike DL, Benton R, Ladin D, Hou Z, et al. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. Journal of Investigative Dermatology. 1995;104:236–240
  4. Burstein NL. Growth factor effects on corneal wound healing. Journal of Ocular Pharmacology. 1987;3:263–277
  5. Calel B, Fagerholm P. Human epidermal growth factor—The influence on the healing of surgically closed corneal wounds. Acta Ophthalmologica Suppl. 1987;182:58–61
  6. Canturk NZ, Vural B, Esen N, Canturk Z, Oktay G, Kirkali G, et al. Effects of granulocyte-macrophage colony-stimulating factor on incisional wound healing in an experimental diabetic rat model. Endocrine Research. 1999;25:105–116
  7. Eming SA, Lee J, Snow RG, Tompkins RG, Yarmush ML, Morgan JR. Genetically modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice—Implications for the use of genetically modified keratinocytes to modulate dermal regeneration. Journal of Investivestigative Dermatology. 1995;105:756–763
  8. Fedyk ER, Jones D, Critchley HO, Phipps RP, Blieden TM, Springer TA. Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing. Journal of Immunology. 2001;166:5749–5754
  9. Froget S, Barthelemy E, Guillot F, Soler C, Coudert MC, Benbunan M, et al. Wound healing mediator production by human dermal fibroblasts grown within a collagen–GAG matrix for skin repair in humans. European Cytokine Network. 2003;14:60–64
  10. Gailit J, Clark RA. Wound repair in the context of extracellular matrix. Current Opinion in Cell Biology. 1994;6:717–725
  11. Greenhalgh DG. The role of growth factors in wound healing. Journal of Trauma. 1996;41:159–167
  12. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. American Journal of Pathology. 1990;136:1235–1246
  13. Groves RW, Schmidt-Lucke JA. Recombinant human GM-CSF in the treatment of poorly healing wounds. Advances in Skin and Wound Care. 2000;13:107–112
  14. Han YP, Tuan TL, Hughes M, Wu H, Garner WL. Transforming growth factor-beta- and tumor necrosis factor-alpha-mediated induction and proteolytic activation of MMP-9 in human skin. Journal of Biological Chemistry. 2001;276:22341–22350
  15. Han YP, Tuan TL, Wu H, Hughes M, Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. Journal of Cell Science. 2001;114:131–139
  16. Holloway GA, Steed DL, DeMarco MJ, Masumoto T, Moosa HH, Webster MW, et al. A randomized, controlled, multicenter, dose response trial of activated platelet supernatant, topical CT-102 in chronic, non-healing, diabetic wounds. Wounds. 1993;5/4:198–206
  17. Hosokawa R, Kikuzaki K, Kimoto T, Matsuura T, Chiba D, Wadamoto M, et al. Controlled local application of basic fibroblast growth factor (FGF-2) accelerates the healing of GBR. An experimental study in beagle dogs. Clinical Oral Implants Research. 2000;11:345–353
  18. Juhasz I, Murphy GF, Yan HC, Herlyn M, Albelda SM. Regulation of extracellular matrix proteins and integrin cell substratum adhesion receptors on epithelium during cutaneous human wound healing in vivo. American Journal of Pathology. 1993;143:1458–1469
  19. Kähäri V-M, Saarialho-Kere UK. Matrix metalloproteinases in skin. Experimental Dermatology. 1997;6:199–213
  20. Ladin D. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee. Plastic and Reconstructive Surgery. 2000;105:1230–1231
  21. Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair and Regeneration. 2002;10:26–37
  22. Lee RH, Efron DT, Tantry U, Stuelten C, Moldawer LL, Abouhamze A, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair and Regeneration. 2000;8:547–553
  23. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia. 2002;45:1011–1016
  24. Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: Mechanisms and therapeutic implications. Diabetes Care. 2005;28:461–471
  25. Lynch SE, Nixon JC, Colvin RB, Antoniades HN. Role of platelet-derived growth factor in wound healing: Synergistic effects with other growth factors. Proceedings of the National Academy of Sciences of the United States of America. 1987;84:7696–7700
  26. Mandracchia VJ, Sanders SM, Frerichs JA. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis. Clinics in Podiatric Medicine and Surgery. 2001;18:189–209
  27. Mast BA, Schultz GS. Interactions of cytokines, growth factors and proteasesin acute and chronic wounds. Wound Repair and Regeneration. 1996;4:420–441
  28. Moyer KE, Saggers GC, Allison GM, Mackay DR, Ehrlich HP. Effects of interleukin-8 on granulation tissue maturation. Journal of Cellular Physiology. 2002;193:173–179
  29. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood–brain barrier during inflammation. American Journal of Physiology. 1998;274:R1203–R1211
  30. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science. 1987;237:1333–1336
  31. Nwomeh BC, Liang H-X, Cohen IK, Yager DR. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. Journal of Surgical Research. 2001;81:189–195
  32. Parkar MH, Kuru L, Giouzeli M, Olsen I. Expression of growth-factor receptors in normal and regenerating human periodontal cells. Archives of Oral Biology. 2001;46:275–284
  33. Parsons SL, Watson SA, Brown PD, Collins HM, Steele JC. Matrix metalloproteinase. British Journal of Surgery. 1997;84:160–166
  34. Payne WG, Ochs DE, Meltzer DD, Hill DP, Mannari RJ, Robson LE, et al. Long-term outcome study of growth factor-treated pressure ulcers. American Journal of Surgery. 2001;181:81–86
  35. Pierce GF, Brown D, Mustoe TA. Quantitative analysis of inflammatory cell influx, procollagen type I synthesis, and collagen cross-linking in incisional wounds: Influence of PDGF-BB and TGF-beta 1 therapy. Journal of Laboratory and Clinical Medicine. 1991;117:373–382
  36. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. Journal of Cellular Biochemistry. 1991;45:319–326
  37. Pierce GF, Tarpley JE, Tseng J, Bready J, Chang D, Kennedy WC, et al. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF in chronic nonhealing wounds. Journal of Clinical Investigation. 1995;96:1336–1350
  38. Pierce GF, Vande BJ, Rudolph R, Tarpley J, Mustoe TA. Platelet-derived growth factor-BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. American Journal of Pathology. 1991;138:629–646
  39. Porras-Reyes BH, Blair HC, Jeffrey JJ, Mustoe TA. Collagenase production at the border of granulation tissue in a healing wound: Macrophage and mesenchymal collagenase production in vivo. Connective Tissue Research. 1991;27:63–71
  40. Quaglino D, Nanney LB, Kennedy R, Davidson JM. Transforming growth factor-beta stimulates wound healing and modulates extracellular matrix gene expression in pig skin: I. Excisional wound model. Laboratory Investigation. 1990;63:307–319
  41. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair. (review) International Journal of Molecular Medicine. 2000;6:391–407
  42. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. Platelet-derived growth factor BB for the treatment of chronic ulcers. Lancet. 1992;339:23–25
  43. Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H, Parks WC, Welgus HG. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. Journal of Clinical Investigation. 1994;94:79–88
  44. Sasaki M, Kashima M, Ito T, Watanabe A, Izumiyama N, Sano M, et al. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1beta and TNF-alpha. Mediators of Inflammation. 2000;9:155–160
  45. Schultz GS, White M, Mitchell R, Brown G, Lynch J, Twardzik DR, et al. Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science. 1987;235:350–352
  46. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:2523–2530
  47. Singer AJ, Clark RA. Cutaneous wound healing. New England Journal of Medicine. 1999;341:738–746
  48. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. Journal of Vascular Surgery. 1995;21:71–78
  49. Stricklin GP, Li L, Jancic V, Wenczak BA, Nanney LB. Localization of mRNAs representing collagenase and TIMP in sections of healing human burn wounds. American Journal of Pathology. 1993;143:1657–1666
  50. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair and Regeneration. 2000;8:13–25
  51. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, et al. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors. Wound Repair and Regeneration. 1999;7:442–452
  52. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: Role of oxidative stress. Circulation Research. 2001;88:1291–1298
  53. Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. Human Pathology. 1999;30:795–802
  54. Vaalamo M, Mattila L, Johansson N, Kariniemi A-L, Karjalainen-Lindsberg M-L, Kähäri V-M, et al. Distinct populations of stromal cells express collagenase-3 (MMP-13) and COllagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. Journal of Investigative Dermatology. 1997;109:96–101
  55. Vaalamo M, Weckroth M, Puolakkainen P, Kere J, Saarinen P, Lauharanta J, et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. British Journal of Dermatology. 1996;135:52–59
  56. Wang JF, Olson ME, Reno CR, Kulyk W, Wright JB, Hart DA. Molecular and cell biology of skin wound healing in a pig model. Connective Tissue Research. 2000;41:195–211
  57. Wieman TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. American Journal of Surgery. 1998;176:74S–79S
  58. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. Journal of Inverstigative Dermatology. 1993;101:64–68
  59. Zhang H, Li C, Baciu PC. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Investigative Ophthalmology & Visual Science. 2002;43:955–962

PII: S1056-8727(05)00059-0

doi: 10.1016/j.jdiacomp.2005.05.013

Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 105-112 , March 2006

Article Tools

* Image Usage & Resolution